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tumour stage (p < 0.04), lymph node metastases (p = 0.04) 
and sessile architecture (p < 0.02). Within a median fol-
low-up of 37.5 months (IQR 20–66), 171 patients (25.2%) 
experienced disease recurrence and 150 (22.1%) died from 
UTUC. In univariable analyses, N-cadherin expression was 
significantly associated with higher probability of recur-
rence (p = 0.01), but not overall (p = 0.9) or cancer-spe-
cific mortality (p = 0.06). When adjusted for the effects of 
all available confounders, N-cadherin was not associated 
with any of the survival outcomes.
Conclusion N-cadherin is expressed in approximately 2/5 
of UTUs. It is associated with adverse pathologic factors 
but not with survival outcomes. Its clinical value remains 
limited.
Keywords N-Cadherin · Urothelial carcinoma · Upper 
tract urothelial carcinoma · UTUC prognosis · Survival · 
Prediction
Abstract 
Purpose To assess the role of N-cadherin as prognostic 
biomarker in patients with upper tract urothelial carcinoma 
(UTUC) in a large multi-institutional cohort of patients.
Patients and methods Immunohistochemistry was used to 
evaluate the status of N-cadherin expression in 678 patients 
with unilateral sporadic UTUC treated with radical neph-
roureterectomy. N-cadherin was considered positive if any 
immunoreactivity with membranous staining was detected. 
The Kaplan–Meier method was used to estimate recurrence-
free survival, overall survival and cancer-specific survival. 
Disease recurrence, overall mortality and cancer-specific 
mortality probabilities were tested in Cox regression models.
Results Expression of N-cadherin was observed in 292 
(43.1%) of patients, and it was associated with advanced 
Electronic supplementary material The online version of this 
article (doi:10.1007/s00345-016-1968-2) contains supplementary 
material, which is available to authorized users.
 * Shahrokh F. Shariat 
 sfshariat@gmail.com
1 Department of Urology, Vienna General Hospital,  
Medical University of Vienna, Vienna, Austria
2 Department of Urology, Urological Research Institute, San 
Raffaele Scientific Institute, Vita-Salute University, Milan, 
Italy
3 Division of Urology, Department of Surgical Sciences, San 
Giovanni Battista Hospital, University of Studies of Torino, 
Turin, Italy
4 Department of Urology, University of Rennes, Rennes, 
France
5 Department of Urology, Pitié-Salpétrière, 
Assistance-Publique Hôpitaux de Paris, Faculté de Médecine 
Pierre et Marie Curie, University Paris VI, Paris, France
6 Department of Urology, University of Texas Southwestern 
Medical Center, Dallas, TX, USA
7 Department of Urology, The University of Texas M.D. 
Anderson Cancer Center, Houston, TX, USA
8 Department of Pathology, Medical University of Vienna, 
Vienna, Austria
9 Karl Landsteiner Institute of Urology and Andrology, Vienna, 
Austria
10 Department of Urology, Weill Cornell Medical College, New 
York, NY, USA
 World J Urol
1 3
Introduction
Upper tract urothelial carcinoma (UTUC) is a relatively 
rare entity that represents 5–10% of Urothelial carcinoma 
(UC) with an estimated incidence of 1–2 cases per 100,000 
inhabitants in western countries [1, 2]. It is still considered 
an aggressive disease with a high incidence of disease pro-
gression and mortality [3, 4]. Radical nephroureterectomy 
(RNU) with bladder cuff excision remains the treatment 
of choice for non-metastatic UTUC [2]. Since periopera-
tive chemotherapy has an essential role in high-risk patient 
and conservative treatment allows the preservation of renal 
functional unit in low-risk patient [2, 5], accurate risk strat-
ification is essential for patient counselling, treatment plan-
ning and follow-up scheduling [6]. Current prognostic and 
predictive tools based on standard clinicopathological fac-
tors remain unfortunately insufficient to yield enough accu-
racy for clinical decision-making [4, 7]. Molecular mark-
ers associated with clinically significant outcome may help 
improve our current prognostication.
Cadherins are transmembrane glycoproteins that play 
a central role in cell–cell adhesion in epithelial tissue [8]. 
N-cadherin is not expressed by normal urothelium but it 
has been demonstrated that N-cadherin expression is asso-
ciated with more invasive phenotype in urothelial carci-
noma and other malignancies [8–10]. Several investigators 
evaluated the prognostic value of different tissue-based 
markers on UC, but only few investigated cadherins’ role in 
UTUC [11–13].
We hypothesized that expression of N-cadherin in RNU 
specimens is associated with more invasive and aggressive 
phenotype and affects oncological outcomes. To assess this, 
we tested the association of N-cadherin with pathologic 
characteristics and prognosis in a large multi-institutional 
cohort of patients treated by RNU for UTUC.
Materials and methods
Patient selection
This is a multi-institutional retrospective study involving 
eight centres from Europe and North America from the 
international UTUC collaboration [14]. All participating 
sites obtained institutional review board approval for the 
study and provided institutional data-sharing agreements 
before the initiation of the study. The initial study cohort 
comprised 753 patients who underwent RNU for UTUC 
between March 1990 and May 2008. Patients who under-
went neo-adjuvant chemotherapy/radiotherapy (n = 19) 
and patients with follow-up duration of <3 months (n = 56) 
were excluded from the study. A total of 678 patients were 
included in the final analysis.
Data collection, pathological evaluation 
and immunohistochemistry
Clinical, pathologic and follow-up data were collected 
from patients’ medical records. Original slides were col-
lected and reviewed by two experienced genitourinary 
pathologists blinded to clinical outcome to ensure the 
validity of pathological data extraction [15]. Pathological 
stage was determined according to the 2002 tumour, node 
and metastasis (TNM) staging system, and tumour grade 
was evaluated in accordance with 1973 WHO grading sys-
tem for patients before 2005 and with both 1973 and 2004 
WHO grading system for specimens collected from 2005 to 
2008 [16]. Tumour architecture was defined as papillary or 
sessile [17]. Lymphovascular invasion (LVI) [18], multifo-
cal tumour [7], carcinoma in situ and tumour necrosis [19] 
were confirmed in every patient. Tumour necrosis in more 
than 10% of tumour area was considered positive for clin-
icopathological association [19].
N-cadherin immunohistochemical staining was per-
formed on formalin-fixed tissue microarray slides in a single 
laboratory with 3 cores per patients evaluated. Four-µm tis-
sue microarray sections were deparaffinized by xylene, rehy-
drated in graded alcohols, treated with 1% hydrogen perox-
ide and submitted to heat-induced epitope retrieval (Dako 
Epitope Retrieval Solution, 40 min, 98 °C). Subsequently, 
antigen retrieval was performed and the primary anti-N-CD 
monoclonal mouse antibody (Transduction Labs, dilution 
1:50 in blocking solution) was incubated for 1 h. Secondary 
antibody (Vector Labs) was applied at a dilution of 1:400. 
Reactivity was visualized with an avidin–biotin complex 
immunoperoxidase system using diamino-benzidine as the 
chromogen and methyl green and alcian blue as the counter-
stain. Positive controls included bladder and prostate tissue 
known to possess N-cadherin expression (external control). 
Negative controls were serial sections processed without 
incubation in primary antibody. E-cadherin immunohisto-
chemical staining has been previously described [20].
Management and follow‑up
Before surgery, all patients underwent full clinical evalu-
ation including history, physical examination, blood tests 
and appropriate imaging study/studies (computed tomog-
raphy, magnetic resonance imaging and chest x-ray). 
All patients underwent RNU [2], but approach was not 
standardized. A regional lymphadenectomy was not rou-
tinely performed. Postoperative follow-up was generally 
performed every 3 months in the first year after surgery, 
every 6 months in the second year and annually thereafter. 
Relapse was defined by local recurrence or distant metas-
tasis. Cause of death was determined by chart review or 
death certificate [21].
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Statistical analyses
Chi-square test was used to assess N-cadherin expres-
sion with categorical variables. Differences in continuous 
variables were analysed using Mann–Whitney U test. The 
Kaplan–Meier method was used to estimate recurrence-free 
survival (RFS), cancer-specific survival (CSS) and over-
all survival (OS); log-rank tests were applied for pairwise 
comparison of survival. Univariable and multivariable Cox 
regression models addressed associations of disease recur-
rence, cancer-specific mortality and overall mortality with 
potential prognostic factors. All p values were two-sided, 
and statistical significance was defined as p < 0.05. Statis-
tical analyses were performed using Stata 11.0 statistical 
software (StataCorp., College Station, TX, USA).
Results
Descriptive characteristics and association 
with N‑cadherin status
Overall, 57% of patients were men and the median age at 
time of surgery was 69 years (IQR 62-76). Expression of 
N-cadherin was observed in 292 patients (43.1%) (Fig. 1). 
Most patients underwent open RNU (78.5%), lymphad-
enectomy was performed in 22.9% of patients, and adju-
vant chemotherapy was given in 10% of patients. Tumours 
were solitary in 78.6% of cases and located in the pelvical-
yceal system in 70.5% of cases. Expression of N-cadherin 
was associated with pathological features such as advanced 
tumour stage (p = 0.04), lymph node metastases (p = 0.04) 
and sessile architecture (p < 0.02) (Table 1).
Concordance between E-cadherin and N-cadherin 
expression status was 45% (supplementary Table 1).
Survival analyses
The median follow-up time was 37.5 months (IQR 20–66). 
During this period, 171 patients (25.2%) experienced 
disease recurrence with median time to recurrence of 
12 months (IQR 5-22); 234 deaths (34.5%) were recorded, 
of which 150 (22.1%) were caused by UTUC. Kaplan–
Meier analysis revealed that patients expressing N-cad-
herin had a lower probability RFS, (log-rank test p = 0.01; 
Fig. 2a) compared to those without N-cadherin expression; 
this was not true for either OS (p = 0.9; Fig. 2b) or CSS 
(p = 0.06; Fig. 2c). 
At univariable cox regression analyses, expression 
of N-cadherin was associated with higher probability of 
recurrence (HR 1.44, 95% CI 1.07–1.95, p = 0.016), but 
not overall mortality (p = 0.9) or cancer-specific mortal-
ity (p = 0.06). Table 2 summarizes the multivariable cox 
regression analyses predicting these outcomes. On multi-
variable analyses that adjusted for the effects of standard 
clinicopathological variables, N-cadherin expression was 
not associated anymore with probabilities of recurrence 
(p = 0.6), overall mortality (p = 0.2) or cancer-specific 
mortality (p = 0.9). Removal of E-cadherin from the multi-
variable analyses did not change the lack of statistical sig-
nificance of N-cadherin with survival outcomes (data not 
shown).
Discussion
In all malignancies, efforts to identify factors associ-
ated with disease recurrence and survival outcomes are of 
utmost importance to set up treatment plans and follow-up 
schedules. In UTUC, precise staging cannot be made until 
RNU is performed; at that point, a proportion of patient 
have already missed the chance to get neo-adjuvant chemo-
therapy and/or regional lymphadenectomy which they may 
have benefited from. The challenge lies in the appropriate 
risk stratification of patients based on standard clinico-
pathological features, together with predictive and prognos-
tic biomarkers [4, 22].
Several investigators studied the prognostic value of 
various tissue-based markers in UTUC such as p53, Ki67, 
EGFR, Snail, Bcl-2, Survivin, β-Catenin and E-cadherin 
[4]. To test the value of one biomarker for this purpose, we 
performed a retrospective multicenter study in which we 
evaluated the association of N-cadherin expression status 
with clinicopathologic features and prognostic outcomes in 
678 patients treated with RNU for UTUC. We found that 
more than two-fifths of patients in this cohort presented 
Fig. 1  Typical outcome of immunohistochemical staining of primary 
urothelial carcinoma of the upper urinary tract with N-cadherin anti-
body
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with abnormal expression of N-cadherin and that expres-
sion was associated with adverse pathological features but 
not survival outcomes.
To the best of our knowledge, only one single-centre 
study evaluated the role of N-cadherin in UTUC [13]. In 
contrast to this study that included only 59 patients, we 
assessed the role of N-cadherin in a large international 
cohort comprising 678 patients. Muramaki et al. [13], stud-
ied the role of N-cadherin as predictor of intra-vesical and 
extra-vesical recurrence but they did not evaluate other 
oncological outcomes such as CSS and OS. We found that 
the expression of N-cadherin is associated with features 
of biologically and clinically aggressive UTUC such as 
advanced T stage and node metastasis. All these factors 
have been previously shown to be independently associ-
ated with poor survival [2, 4, 6, 23]. While association with 
pathologic factors is important, only association with sur-
vival outcomes will change management of UTUC patients 
and we failed to demonstrate an association of N-cadherin 
expression with oncological survival outcomes on multivar-
iable analysis, limiting its prognostic value in clinical prac-
tice. In comparison with reports evaluating the association 
Table 1  Descriptive 
characteristics for the cohort of 
678 patients with upper tract 
urothelial carcinoma treated 
with radical nephroureterectomy
CIS carcinoma of situ
Variables Total N-cadherin status p value
Negative Positive
Number of patients n (%) 678 (100) 386 (56.9%) 292 (43.1%)
Median age (IQR), years 69 (63–76) 70 (62–76) 69 (63–76) 0.1
Gender, n (%) 0.7
 Female 298 (44) 167 (43) 131 (45)
 Male 380 (56) 219 (57) 161 (55)
Previous bladder cancer, n (%) 247 (36) 135 (35) 112 (38) 0.4
Side, n (%) 0.8
 Right 307 (45.3) 176 (45.6) 131 (44.9)
 Left 371 (54.7) 210 (54.4) 161 (55.1)
Type of surgery, n (%) 0.4
 Open 532 (78.5) 307 (79.5) 225 (77)
 Laparoscopy 146 (21.5) 79 (20.5) 67 (23)
Lymphadenectomy, n (%) 155 (22.9) 82 (21.2) 73 (25) 0.2
Tumour location, n (%) 0.001
 Pelvicalyceal 478 (70.5) 291 (75.4) 187 (64)
 Ureter 200 (29.5) 95 (24.6) 105 (36)
Tumour architecture, n (%) 0.02
 Papillary 558 (82.3) 329 (85.2) 229 (78.4)
 Sessile 120 (17.7) 57 (14.8) 63 (21.6)
Multifocal tumour, n (%) 145 (21.4) 82 (21.2) 63 (21.6) 0.9
Pathological tumour stage, n (%) 0.04
 pTa, pTis 121 (17.8) 78 (20.2) 43 (14.7)
 pT1 208 (30.7) 127 (32.9) 81 (27.7)
 pT2 123 (18.1) 61 (15.8) 62 (21.2)
 pT3 193 (28.5) 106 (27.5) 87 (29.8)
 pT4 33 (4.9) 14 (3.6) 19 (6.5)
Concomitant CIS, n (%) 128 (18.9) 63 (16.3) 65 (22.3) 0.05
Lymph node metastases, n (%) 49 (7.2) 21 (5.4) 28 (9.6) 0.04
Grade, n (%) 0.2
 Low 174 (25.7) 107 (27.7) 67 (23)
 High 504 (72.3) 279 (72.3) 225 (77)
Lympho-vascular invasion, n (%) 135 (19.9) 69 (17.9) 66 (22.6) 0.1
Necrosis, n (%) 81 (12) 42 (10.9) 39 (13.4) 0.3
Adjuvant chemotherapy, n (%) 68 (10) 34 (8.8) 34 (11.6) 0.2
E-cadherin, n (%) 353 (52.1) 194 (50.3) 159 (54.5) 0.3
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Fig. 2  Kaplan–Meier estimates 
for a disease-free survival, b 
overall survival and c cancer-
specific survival according 
to N-cadherin status in 678 
patients treated with radical 
nephroureterectomy for upper 
tract urothelial carcinoma
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between N-cadherin and urothelial carcinoma of bladder, 
the percentage of expression of N-cadherin in UTUC in 
this study was within the range detected in bladder cancer 
reports [24–26] and lower than the previously reported in 
UTUC (43 vs 68%) [13]. Such discrepancies may be due 
to differences in staining and case mix of the population at 
hand. Moreover, the expression of N-cadherin in bladder 
cancer reports was higher in muscle invasive bladder can-
cer compared to non-muscle invasive bladder cancer. Nor-
mal urothelium did not show N-cadherin expression [8].
Since UC is a heterogeneous disease with complex 
underlying molecular mechanism, multiple biomark-
ers should be integrated into prognostic schemes to accu-
rately guide our decision-making process [27–29]. In 
epithelial malignancies, epithelial cells undergo series of 
changes in morphology, adhesion and migratory capacity 
turning them into cells with mesenchymal characteristics, 
this process is called epithelial mesenchymal transitional 
(EMT) [30]. Many investigators studied more than one 
biomarker simultaneously [29], demonstrating the process 
of downregulation of epithelial markers and upregulation 
of mesenchymal markers, named as “cadherin switch” [8, 
14]. Here comes the importance of studying other poten-
tial candidates implicated in carcinogenesis and invasive 
properties of urothelial carcinoma such as E and/or P-cad-
herin. For example, Muramaki et al. [13] addressed the 
effect of both N and E-cadherin expression on intra- and 
extra-vesical recurrence after RNU and they found that 
decrease in expression of E-cadherin and increase expres-
sion of N-cadherin is an independent prognostic factor for 
disease recurrence, a finding that goes in line with the cad-
herin switch concept. Also, several transcriptional factors 
play a role in suppression of epithelial markers and promo-
tion of mesenchymal markers like snail, vimentin, slug and 
twist. These factors may also be used for prognostication or 
evaluated as a potential candidate for targeted therapy.
Since EMT process involves multiple markers and tran-
scriptional factors in dynamic fashion, we analysed the data 
by making subgroup according to cadherin status. Patients 
with negative expression of E-cadherin were evaluated for 
possible association between N-cadherin and survival out-
comes; no such association could be made. Similarly, in 
patients with positive E-cadherin expression association 
between N-cadherin and survival outcomes were assessed 
but also no such association could be made (supplemen-
tary Tables 1 and 2). In addition, removal of E-cadherin on 
multivariable cox regression analyses did not significantly 
change the statistical association between N-cadherin and 
survival outcomes.
Although we have found limited role of N-cadherin in 
prognostication and decision-making, the promise lies in 
other markers that could serve our main goal in improving 
the pre-operative risk stratification of patients with UTUC. 
Tissue-based, blood-based, urinary and genetic markers are 
Table 2  Multivariable Cox regression analyses predicting disease recurrence, overall and cancer-specific mortality of 678 patients treated with 
radical nephroureterectomy for upper tract urothelial carcinoma
CI confidence interval, HR hazard ratio, CIS carcinoma in situ
Variable Disease recurrence Overall mortality Cancer-specific mortality
HR 95% CI p HR 95% CI p HR 95% CI p
Age (continuous) 1.02 1.01–1.04 0.004 1.04 1.03–1.06 <0.001 1.02 1.01–1.04 0.004
Female gender 0.71 0.52–0.97 0.036 0.92 0.71–1.20 0.6 0.77 0.55–1.07 0.1
Sessile architecture 1.33 0.90–1.97 0.1 1.28 0.91–1.81 0.2 1.41 0.93–2.14 0.1
pT stage
(ref.: pTa, pTis)
pT1 1.67 0.70–3.97 0.2 1.02 0.58–1.80 0.9 1.44 0.56–3.72 0.4
pT2 3.49 1.48–8.22 0.004 1.54 0.86–2.74 0.1 3.42 1.36–8.61 0.009
pT3 6.8 3.00–15.53 <0.001 2.60 1.50–4.51 0.001 5.96 2.45–14.49 <0.001
pT4 27.3 11.7–81.0 <0.001 9.17 4.47–18.79 <0.001 22.7 7.9–61.71 <0.001
pN + stage 2.21 1.43–3.39 <0.001 1.94 1.27–2.90 0.002 2.37 1.52–3.69 <0.001
Concomitant CIS 1.35 0.92–1.99 0.1 1.13 0.81–1.63 0.4 1.10 0.72–1.68 0.7
High grade 1.33 0.79–2.24 0.3 1.63 1.04–2.48 0.03 1.52 0.85–2.72 0.1
Lymphovascular invasion 1.17 0.81–1.69 0.4 1.23 0.90–1.74 0.2 1.32 0.89–1.94 0.2
Necrosis 0.50 0.30–0.81 0.005 0.78 0.53–1.19 0.3 0.51 0.31–0.85 0.01
Multifocal 1.61 1.12–2.31 0.009 1.59 1.17–2.15 0.002 1.76 1.20–2.56 0.003
E-cadherin 1.01 0.73–1.41 0.9 0.99 0.74–1.31 0.9 0.95 0.67–1.36 0.8
N-cadherin 1.09 0.79–1.51 0.6 0.83 0.64–1.12 0.2 1.01 0.72–1.43 0.9
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collectively the fields for future research [4]. For tissue-
based makers, exploration of biomarkers related to cellular 
processes such as cell adhesions, angiogenesis and apopto-
sis is an essential need not only for prognostication but also 
for identifying possible therapeutic targets.
This study is not without limitations; the most obvious is 
the retrospective and multicenter nature of data collection 
which may lead to inconsistencies in surgical technique, stag-
ing and laboratory evaluation that may cofound outcomes. 
Additionally, to incorporate molecular markers into prog-
nostic model, a prospective study is required. The second 
limitation is the reliability of immunohistochemical technique 
which is semiquantative and depends on a range of variables 
such as fixation techniques, preservation, variability in inter-
pretation, scoring protocol and choice of antibodies with its 
related lack of reproducibility. To overcome some of these 
variables, we used tissue TMA with an autostainer and auto-
mated scoring system based on bright-field microscopy imag-
ing coupled with advanced colour detection software.
Conclusion
N-cadherin expression is associated with adverse clinico-
pathologic features and higher probability of recurrence 
on univariable analyses in patients undergoing RNU for 
UTUC. However, when adjusted to the effect of standard 
prognostic factors on multivariable analyses, this effect dis-
appears, limiting its role in decision-making. Finally, more 
efforts should be made to find out markers to be incorpo-
rated in prognostic schemes in order to help in clinical 
decision-making process at each UTUC disease state.
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